Latest fiscal year 2020 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2020, Cogent Biosciences, Inc. reported revenue of $8M. Operating margin was -1044.3% and net margin -950.4%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from COGT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2020 | $8M | -1044.3% | -950.4% |
How does COGT compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.